A Drosophila model for the electrophile counter-attack chemoprevention strategy
亲电子反击化学预防策略的果蝇模型
基本信息
- 批准号:7151900
- 负责人:
- 金额:$ 7.7万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2006
- 资助国家:美国
- 起止时间:2006-08-08 至 2008-07-31
- 项目状态:已结题
- 来源:
- 关键词:
项目摘要
DESCRIPTION (provided by applicant): The long-term objective of this application is to accelerate cancer chemoprevention research by establishing Drosophila melanogaster as a platform for the genetic and pharmacological study of Keap1-Nrf2 signaling. Preliminary findings suggest that the Drosophila homologues of Nrf2 and Keap1 (CNC-C and dKeap1, respectively) comprise a cell protective module that responds to oxidants and to the chemopreventive agent oltipraz, regulates stress-inducible genes, and confers increased tolerance of the fly to oxidative stress. This project will characterize the effects of oltipraz and of the new synthetic triterpenoids (provided by Dr Michael B. Sporn, Dartmouth Medical School) on the activation of Drosophila Nrf2 (CNC-C) signaling. Functional experiments will determine the mechanisms of action and physiological effects of these chemopreventive drugs in Drosophila. By conducting experiments in genetic backgrounds of gain- or loss-of-function for Nrf2 or Keap1 that have been developed in the laboratory of the applicant, the signaling pathway mediating the activation of the Anti-oxidant Response Element and the expression of Nrf2 target genes will be charted. Biological assays will monitor the effects of oltipraz and triterpenoids on the organism's resistance to oxidative stressors and on its lifespan. Together, these experiments will establish a genetically tractable system for studying the effects of pharmacological manipulation of Nrf2 signaling in an intact organism that is complementary to existing rodent, fish, and cell-based model systems. This work will be the starting point from which the power of Drosophila genetics will help to address crucial clinical issues of chemoprevention. Future research that will become feasible upon completion of these pilot studies will analyze the integration of the Nrf2 system with other mechanisms of stress response and defense in vivo, providing a basis for rational design of combinatorial targeting strategies. Furthermore, the evaluation of long-term organismal effects of chemopreventive agents in Drosophila could help prioritize drugs with quality-of-life promoting profiles for further preclinical development. Finally, Drosophila could become a platform for rapid in vivo structure-activity relationship (SAR) analyses of Nrf2 activators.
描述(由申请人提供):本申请的长期目标是通过将黑腹果蝇建立为Keap 1-Nrf 2信号传导的遗传和药理学研究平台来加速癌症化学预防研究。初步研究结果表明,果蝇同源物Nrf 2和Keap 1(CNC-C和dKeap 1,分别)包括一个细胞保护模块,响应氧化剂和化学预防剂oltipraz,调节应激诱导基因,并赋予增加的耐受性的苍蝇氧化应激。该项目将描述奥替普拉和新合成三萜类化合物(由Michael B博士提供)的作用。Sporn,达特茅斯医学院)对果蝇Nrf 2(CNC-C)信号传导激活的研究。功能实验将确定这些化学预防药物在果蝇中的作用机制和生理效应。通过在申请人实验室开发的Nrf 2或Keap 1功能获得或丧失的遗传背景中进行实验,将绘制介导抗氧化反应元件活化和Nrf 2靶基因表达的信号通路。生物测定将监测奥替普拉和三萜类化合物对生物体抗氧化应激和寿命的影响。总之,这些实验将建立一个遗传学上易于处理的系统,用于研究完整生物体中Nrf 2信号传导的药理学操作的影响,该系统与现有的啮齿动物,鱼类和基于细胞的模型系统互补。这项工作将是果蝇遗传学的力量将有助于解决化学预防的关键临床问题的起点。在这些初步研究完成后,未来的研究将成为可行的,将分析Nrf 2系统与体内应激反应和防御的其他机制的整合,为合理设计组合靶向策略提供基础。此外,对果蝇中化学预防剂的长期生物效应的评估可以帮助优先考虑具有生活质量促进特征的药物,以进一步进行临床前开发。最后,果蝇可以成为一个平台,在体内快速的结构-活性关系(SAR)分析的Nrf 2激活剂。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Dirk Bohmann其他文献
Dirk Bohmann的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Dirk Bohmann', 18)}}的其他基金
Nrf2 as a regulator of health span and aging
Nrf2 作为健康跨度和衰老的调节因子
- 批准号:
8519191 - 财政年份:2011
- 资助金额:
$ 7.7万 - 项目类别:
Nrf2 as a regulator of health span and aging
Nrf2 作为健康跨度和衰老的调节因子
- 批准号:
8309129 - 财政年份:2011
- 资助金额:
$ 7.7万 - 项目类别:
Nrf2 as a regulator of health span and aging
Nrf2 作为健康跨度和衰老的调节因子
- 批准号:
8707921 - 财政年份:2011
- 资助金额:
$ 7.7万 - 项目类别:
Nrf2 as a regulator of health span and aging
Nrf2 作为健康跨度和衰老的调节因子
- 批准号:
8087651 - 财政年份:2011
- 资助金额:
$ 7.7万 - 项目类别:
Regulation of Cell-Cell Interactions by Matrix Metalloproteases
基质金属蛋白酶对细胞间相互作用的调节
- 批准号:
8033391 - 财政年份:2010
- 资助金额:
$ 7.7万 - 项目类别:
Regulation of Cell-Cell Interactions by Matrix Metalloproteases
基质金属蛋白酶对细胞间相互作用的调节
- 批准号:
8392264 - 财政年份:2010
- 资助金额:
$ 7.7万 - 项目类别:
相似海外基金
Evaluating the effectiveness and sustainability of integrating helminth control with seasonal malaria chemoprevention in West African children
评估西非儿童蠕虫控制与季节性疟疾化学预防相结合的有效性和可持续性
- 批准号:
MR/X023133/1 - 财政年份:2024
- 资助金额:
$ 7.7万 - 项目类别:
Fellowship
Stress adaptation in obesity-associated pancreatic cancer
肥胖相关胰腺癌的压力适应
- 批准号:
10581170 - 财政年份:2023
- 资助金额:
$ 7.7万 - 项目类别:
Epigallocatechin gallate for prevention of lethal cirrhosis complications
表没食子儿茶素没食子酸酯用于预防致命性肝硬化并发症
- 批准号:
10713745 - 财政年份:2023
- 资助金额:
$ 7.7万 - 项目类别:
Clinical breast cancer risk prediction models for women with a high-risk benign breast diagnosis
高风险良性乳腺诊断女性的临床乳腺癌风险预测模型
- 批准号:
10719777 - 财政年份:2023
- 资助金额:
$ 7.7万 - 项目类别:
Applying Population Management Best Practices to Preventive Genomic Medicine
将人口管理最佳实践应用于预防性基因组医学
- 批准号:
10674202 - 财政年份:2023
- 资助金额:
$ 7.7万 - 项目类别:
Intensive cholesterol-lowering intervention and anti-tumor immunity modeled in prostate cancer
以前列腺癌为模型的强化降胆固醇干预和抗肿瘤免疫
- 批准号:
10802975 - 财政年份:2023
- 资助金额:
$ 7.7万 - 项目类别:
Examining the mechanisms and optimization of malaria chemoprevention strategies to improve birth outcomes in Africa
检查疟疾化学预防策略的机制和优化,以改善非洲的出生结果
- 批准号:
10642646 - 财政年份:2023
- 资助金额:
$ 7.7万 - 项目类别:
Targeting cancer stem-like cells and inflammation for colon cancer chemoprevention
针对癌症干细胞样细胞和炎症进行结肠癌化学预防
- 批准号:
10650910 - 财政年份:2023
- 资助金额:
$ 7.7万 - 项目类别: